Skip to content

US · KARD · BIOTECHNOLOGY

Kardigan, Inc. (KARD) intrinsic value and stock valuation

$16.64as of 2026-09-18 · Mkt cap 1.55B

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kardigan, Inc. DCF and intrinsic value

InvestorsCraft values KARD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KARD’s statements →

Kardigan, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Princeton, NJ, US kardigan.bio

How the business is doing

Fiscal 2025–2025, USD

Revenue
$0.00
20252025
Net income
-$-191.94T
20252025
Free cash flow
-$-157.7T
20252025
Total equity
-$-250.34T
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
FY
Revenue$0.00
Operating income-$-201.84T
Net income-$-191.94T
EPSd-$-3.2M
Operating cash flow-$-151.06T
Capital expenditure-$-6.64T
Free cash flow-$-157.7T
Total assets$390.9T
Total debt$13.8T
Net debt-$-95.16T
Total equity-$-250.34T
Cash and short-term investments$335.5T
Income statement
FY
Revenue$0.00
Cost of revenue$0.00
Gross profit$0.00
Research and development expenses$153.1T
Selling, general and administrative expenses$48.8T
Other expenses$0.00
Operating expenses$201.8T
Cost and expenses$201.8T
Interest income$6.85T
Interest expense$0.00
Depreciation and amortization$5.85T
Ebitda-$-195.99T
Operating income-$-201.84T
Total other income/expenses, net$5.38T
Income before tax-$-196.45T
Income tax expense-$-4.51T
Net income-$-191.94T
Weighted average shares outstanding$60T
Weighted average diluted shares outstanding$60T
Balance sheet
FY
Cash and short-term investments$335.5T
Net receivables$0.00
Inventory$0.00
Total current assets$345.4T
Property, plant and equipment, net$18.2T
Goodwill and intangible assets$23.2T
Long-term investments$0.00
Total non-current assets$45.6T
Total assets$390.9T
Accounts payable$7.99T
Short-term debt$3.14T
Deferred revenue$0.00
Total current liabilities$37.5T
Long-term debt$10.7T
Deferred revenue, non-current$0.00
Total non-current liabilities$603.7T
Capital lease obligations$13.8T
Total liabilities$641.3T
Common stock$0.00
Retained earnings-$-281.09T
Accumulated other comprehensive income (loss)$63B
Total equity-$-250.34T
Total investments$226.5T
Total debt$13.8T
Net debt-$-95.16T
Cash flow statement
FY
Net income-$-191.94T
Depreciation and amortization$5.85T
Stock-based compensation$15.9T
Change in working capital$6.43T
Accounts receivable$0.00
Inventory$0.00
Accounts payable$1.76T
Net cash provided by operating activities-$-151.06T
Investments in property, plant and equipment-$-5.08T
Acquisitions, net-$-3.96T
Net cash used for investing activities-$-237.04T
Common stock issued$561B
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities$447.8T
Net change in cash$59.7T
Cash at end of period$109.5T
Operating cash flow-$-151.06T
Capital expenditure-$-6.64T
Free cash flow-$-157.7T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kardigan, Inc.

        Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

        CEO
        Tassos Gianakakos
        Employees
        241
        Beta
        0.00

        Explore

        Frequently asked questions

        What is the intrinsic value of Kardigan, Inc. (KARD)?

        InvestorsCraft does not currently publish an intrinsic value for KARD. How the IC value is calculated.

        Is KARD undervalued?

        InvestorsCraft does not publish an undervaluation signal for KARD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.